SHMLF (SHL Telemedicine) EBIT: $-13.52 Mil (TTM As of Dec. 2025)

What is SHL Telemedicine EBIT?

SHL Telemedicine SHMLF 51 EBIT is $-13.52 Mil as of Dec. 2025. GuruFocus rates SHMLF with a GF Score™ of 51/100 and a GF Value™ of $13.95. The stock has 3 warning signs investors should review.

SHL Telemedicine's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $-10.26 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-13.52 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. SHL Telemedicine's annualized ROC % for the quarter that ended in Dec. 2025 was -5.66%. SHL Telemedicine's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -223.60%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. SHL Telemedicine's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -45.82%.

SHL Telemedicine (OTCPK:SHMLF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

SHL Telemedicine's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-3.938 * ( 1 - 0% )	/	( (68.636	+	70.436)	/ 2 )
=	-3.938	/	69.536
=	-5.66 %

where

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	77.014	-	11.729	-	( 13.08	-	max(0, 25.876	-	22.525	+	13.08	))
=	68.636

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	84.62	-	6.96	-	( 25.273	-	max(0, 29.021	-	36.245	+	25.273	))
=	70.436

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

SHL Telemedicine's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-20.52	/	( ( (9.765 + max(-12.705, 0))	+	(8.589 + max(-14.125, 0)) )	/	2 )
=	-20.52	/	( ( 9.765	+	8.589 )	/	2 )
=	-20.52	/	9.177
=	-223.60 %

where Working Capital is:

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(7.337	+	1.211	+	0)	-	(11.729	+	0	+	9.524)
=	-12.705

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(8.65	+	1.33	+	0.674)	-	(6.96	+	0	+	17.819)
=	-14.125

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

SHL Telemedicine's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	-13.519	/	29.506
	=	-45.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SHL Telemedicine EBIT Related Terms

SHL Telemedicine EBIT Historical Data

* Premium members only.

The historical data trend for SHL Telemedicine's EBIT can be seen below:

SHL Telemedicine EBIT Chart

SHL Telemedicine Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-12.94

2.35

-4.67

-25.69

-13.52

SHL Telemedicine Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
EBIT	Get a 7-Day Free Trial															-4.68	-2.61	-23.09	-3.26	-10.26

SHMLF vs VEEV, BTSG, TEM: EBIT Comparison

For the Health Information Services subindustry, SHL Telemedicine's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SHL Telemedicine EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SHL Telemedicine's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SHL Telemedicine's EV-to-EBIT falls into.

Save Embed

51GF Score

SHL Telemedicine Ltd SHMLF

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

SHL Telemedicine EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-13.52 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-13.52 Mil mean?

SHL Telemedicine (SHMLF) has a EBIT of $-13.52 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on SHL Telemedicine.

Is SHL Telemedicine's EBIT too high?

SHL Telemedicine's current EBIT is $-13.52 Mil. Overall, SHL Telemedicine has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.

How does SHL Telemedicine's EBIT compare to VEEV and BTSG?

SHL Telemedicine's EBIT of $-13.52 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Healthcare Providers & Services company?

A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on SHL Telemedicine. SHL Telemedicine's current EBIT is $-13.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is SHL Telemedicine stock overvalued right now?

SHL Telemedicine (SHMLF) has a current EBIT of $-13.52 Mil. The stock's GF Value™ is $13.95, compared to a current price of $4.84 — trading 65.3% below its estimated fair value. The current EBIT is $-13.52 Mil. SHL Telemedicine's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For SHL Telemedicine (SHMLF), the current EBIT is $-13.52 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SHL Telemedicine (SHMLF) Overvalued in 2026?

Based on GuruFocus' analysis, SHL Telemedicine stock appears to be undervalued. The current stock price of $4.84 is trading 65.3% below its estimated GF Value™ of $13.95.

Key valuation signals for SHMLF:

EBIT: $-13.52 Mil
GF Value™: $13.95 vs. price of $4.84 (65.3% below fair value)
GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the SHMLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SHL Telemedicine Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies VEEV BTSG ASX:PME TEM HQY TSE:2413 HKSE:02228 HNGE DOCS WAY TXG NSE:IKS PRVA HTFL SZSE:300253 HKSE:01833 NSE:SAGILITY OMCL SGX:ULG TDOC

Other Exchanges 0QMX:UK SHLTN:Switzerland

Address 90 Yigal Alon Street, Tel Aviv, ISR, 67891

Website https://www.shl-telemedicine.com

SHL Telemedicine Ltd develops and markets personal telemedicine solutions. The company consists of the transmission of medical data by an individual, from a remote location to a medical call center, through telecommunication networks. The company provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments are Israel, Europe, and the rest of the world, out of which majority of revenue comes from Israel.

51GF Score

Get the complete analysis for SHMLF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.84

Price

$13.95

GF Value

View SHMLF Analysis

See EBIT data for all stocks →